Caris director granted 13,192 RSUs in CAI stock

Q: What did Peter M. Castleman report in this Form 4 for CAI?

Peter M. Castleman reported an award of 13,192 restricted stock units of Caris Life Sciences, Inc. Common Stock on 2026-08-14, increasing his directly held shares to 29,321 after the transaction.

Q: How many Caris Life Sciences (CAI) shares does Castleman now hold directly and indirectly?

After the reported award, Castleman holds 29,321 shares directly, 108,009 shares indirectly through a family trust, and 10,546,384 shares indirectly through CLS-PF-SPE, LLC, subject to a pecuniary-interest-based beneficial ownership disclaimer.

Q: Was the CAI Form 4 transaction by Peter Castleman a purchase or a grant?

The Form 4 reports a grant/award acquisition, not an open-market purchase. Castleman received 13,192 restricted stock units with a per-share transaction price of $0.0000, vesting under the applicable grant agreement.

Q: What does the Form 4 say about Castleman’s interest in CLS-PF-SPE, LLC’s CAI shares?

The filing states that CLS-PF-SPE Manager, LLC manages CLS-PF-SPE, LLC and Castleman, as a manager, has voting and investment power, but he disclaims beneficial ownership of the 10,546,384 shares except for his pecuniary interest.

Q: Are Peter Castleman’s CAI transactions under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not affirmed (set to false), and the footnotes do not state that the 13,192-share restricted stock unit award was made pursuant to a Rule 10b5-1 trading plan.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Caris Life Sciences director Peter M. Castleman reported an acquisition of 13,192 shares of Common Stock on 2026-08-14, as an award of restricted stock units that vest in accordance with the applicable grant agreement, bringing his directly held shares to 29,321.

He also reports indirect ownership of 108,009 shares held by a family trust and 10,546,384 shares held by CLS-PF-SPE, LLC, where he has voting and investment power through a manager role and disclaims beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

Grant/Award: 13,192 shares

Grant/Award 3 txns

Insider CASTLEMAN PETER M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock ^F1	13,192	$0.00	$0.00
holding	Common Stock	--	--	--
holding	Common Stock ^{F2, F3}	--	--	--

Holdings After Transaction: Common Stock — 29,321 shares (Direct); Common Stock — 108,009 shares (Indirect, By Family Trust); Common Stock — 10,546,384 shares (Indirect, By CLS-PF-SPE, LLC)

Footnotes (3)

F1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
F2. Includes shares received in pro rata distributions exempt pursuant to Rule 16a-9.
F3. CLS-PF-SPE Manager, LLC is the manager of CLS-PF-SPE, LLC. Mr. Castleman is a manager of CLS-PF-SPE Manager, LLC and in such capacity has voting and investment power with respect to the shares held by CLS-PF-SPE, LLC. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Key Figures

RSU award: 13,192 shares Direct holdings after award: 29,321 shares Indirect family trust holdings: 108,009 shares +2 more

5 metrics

RSU award 13,192 shares Award of restricted stock units on 2026-08-14

Direct holdings after award 29,321 shares Common Stock directly held following the 13,192-share award

Indirect family trust holdings 108,009 shares Common Stock held indirectly by family trust

Indirect CLS-PF-SPE, LLC holdings 10,546,384 shares Common Stock held indirectly by CLS-PF-SPE, LLC

RSU grant price $0.0000 per share Per-share transaction price for the 13,192-share restricted stock unit award

Key Terms

restricted stock units, pro rata distributions, Rule 16a-9, pecuniary interest

4 terms

restricted stock units financial

"Represents an award of restricted stock units which vest in accordance"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

pro rata distributions financial

"Includes shares received in pro rata distributions exempt pursuant"

Rule 16a-9 regulatory

"Includes shares received in pro rata distributions exempt pursuant to Rule 16a-9."

pecuniary interest financial

"The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Peter M. Castleman report in this Form 4 for CAI?

Peter M. Castleman reported an award of 13,192 restricted stock units of Caris Life Sciences, Inc. Common Stock on 2026-08-14, increasing his directly held shares to 29,321 after the transaction.

How many Caris Life Sciences (CAI) shares does Castleman now hold directly and indirectly?

After the reported award, Castleman holds 29,321 shares directly, 108,009 shares indirectly through a family trust, and 10,546,384 shares indirectly through CLS-PF-SPE, LLC, subject to a pecuniary-interest-based beneficial ownership disclaimer.

Was the CAI Form 4 transaction by Peter Castleman a purchase or a grant?

The Form 4 reports a grant/award acquisition, not an open-market purchase. Castleman received 13,192 restricted stock units with a per-share transaction price of $0.0000, vesting under the applicable grant agreement.

What does the Form 4 say about Castleman’s interest in CLS-PF-SPE, LLC’s CAI shares?

The filing states that CLS-PF-SPE Manager, LLC manages CLS-PF-SPE, LLC and Castleman, as a manager, has voting and investment power, but he disclaims beneficial ownership of the 10,546,384 shares except for his pecuniary interest.

Are Peter Castleman’s CAI transactions under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not affirmed (set to false), and the footnotes do not state that the 13,192-share restricted stock unit award was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/14/2026 - 05:44 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CASTLEMAN PETER M

(Last)

(First)

(Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING

TEXAS

75039

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/14/2026		A		13,192⁽¹⁾	A	$0	29,321	D
Common Stock								108,009	I	By Family Trust
Common Stock								10,546,384⁽²⁾	I	By CLS-PF-SPE, LLC⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

2. Includes shares received in pro rata distributions exempt pursuant to Rule 16a-9.

3. CLS-PF-SPE Manager, LLC is the manager of CLS-PF-SPE, LLC. Mr. Castleman is a manager of CLS-PF-SPE Manager, LLC and in such capacity has voting and investment power with respect to the shares held by CLS-PF-SPE, LLC. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR